Last reviewed · How we verify
NCT06089759
Performance and Safety of the Lipo-transfer Cannulas in Patients Underlying Lipofilling Treatment
trial in Lipodystrophy in 108 participants. Completed in 31 July 2024.
1 July 2024
Quick facts
| Lead sponsor | Aesthetic Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 108 |
| Start date | 30 August 2023 |
| Primary completion | 1 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 3 locations across France |
Conditions studied
- Lipodystrophy — all drugs for Lipodystrophy →
- Deformities — all drugs for Deformities →
Sponsor
Aesthetic Group
Who can join
18 and older, any sex, with Lipodystrophy or Deformities. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this post-market clinical follow up study is to assess the safety and performance of Aesthetic Group cannulas. The study will evaluate the outcome of the Aesthetic Group cannulas range over a period of 1 month after intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06089759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lipodystrophy
Currently open trials in the same condition.
- NCT05996536 — Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD) · recruiting
- NCT06236932 — Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE" · NA · recruiting
- NCT05789251 — Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunni · NA · recruiting
- NCT05419037 — Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy · recruiting
- NCT02262806 — Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06089759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aesthetic Group
- Last refreshed: 1 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06089759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing